Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from 4DMedical Ltd ( (AU:4DX) ).
4DMedical Limited has renewed a three-year contract with the University of Michigan Medical Center, valued at approximately AUD$155,000, allowing the institution to utilize its comprehensive suite of structural lung analysis products. This renewal underscores the trust and value placed on 4DMedical’s technology by leading US institutions. Additionally, a recent multicenter study published in Respiratory Research highlighted the effectiveness of 4DMedical’s X-ray Velocimetry Lung Ventilation Analysis Software in detecting subtle lung diseases, offering actionable insights for patient care. The company also secured a AUD$1.1 million grant to advance AI lung function analysis, further solidifying its position as a pioneer in pulmonary imaging.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$0.76 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
More about 4DMedical Ltd
4DMedical Limited is a global leader in respiratory imaging technology, providing advanced lung analysis tools. The company focuses on developing innovative imaging solutions to enhance the diagnosis and monitoring of pulmonary diseases, with a market focus on healthcare institutions and research centers.
Average Trading Volume: 848,281
Technical Sentiment Signal: Sell
Current Market Cap: A$116.4M
Learn more about 4DX stock on TipRanks’ Stock Analysis page.